Skip to content
The Policy VaultThe Policy Vault

KineretCareFirst (Caremark)

Immune checkpoint inhibitor-related toxicity

Initial criteria

  • Member has immunotherapy-related hemophagocytic lymphohistiocytosis (HLH)-like syndrome.
  • Member has had an inadequate response to systemic corticosteroids OR has an intolerance or contraindication to corticosteroids.

Approval duration

6 months